NBY רווח למניה בשנים עשר החודשים האחרונים NovaBay

How can one manage the pressure of price wars and the risk of losing loyalty in the over-the-counter segment? The rolling 12-month EPS reflects current dynamics, where the parameter has stabilized at -7.43. The stable income of NovaBay Pharmaceuticals (NBY) is based on patient habits regarding ophthalmic antiseptics, while Avenova's high reputation among US physicians guarantees business resilience.
NovaBay - פילוחים אנליטיים ומדדי מפתח (NBY)

When screening for issuer reliability, analyzing the actual capital growth per share becomes key. This metric is calculated as the ratio of total annual net income to the average number of shares outstanding. For NovaBay Pharmaceuticals (NBY), this calculation reflects the efficiency of scaling ophthalmology product sales through contract manufacturing. The current annual net income per share confirms the business's ability to generate profit without capital expenditures on manufacturing plants.